Duyuru • Mar 02
NovAccess Global Inc., Annual General Meeting, May 06, 2024 NovAccess Global Inc., Annual General Meeting, May 06, 2024, at 12:00 US Eastern Standard Time. Duyuru • Feb 29
NovAccess Global Inc. announced that it has received $0.1 million in funding from AJB Capital Investments LLC NovAccess Global Inc. announced that it has entered into a securities purchase agreement to issue a promissory note in the principal amount of up to $100,000 on February 27, 2024, The transaction will include participation from new investor, AJB Capital Investments LLC. The notes will have a coupon rate of 12% and the note is due on August 27, 2024. Duyuru • Feb 16
NovAccess Global Inc. announced delayed 10-Q filing On 02/15/2024, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Duyuru • Nov 11
NovAccess Global Inc. Appoints Roscoe M. Moore, Jr. to Scientific Advisory Board NovAccess Global Inc. announced the appointment of Dr. Roscoe M. Moore, Jr., to its Scientific Advisory Board. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General. The addition of Dr. Moore brings the NovAccess Global Scientific Advisory Board to 6 members. NovAccess Global intends to leverage the expertise, insight and professional network of Dr. Moore with NIH and other healthcare centers of influence toward accessing government non-dilutive funding, including the White House Cancer Moonshot, amongst other targeted award mechanisms. Dr. Moore will be tapped to assist NovAccess Global to develop collaborations here in the US and overseas. Through Dr. Moore, NovAccess Global will strive to initiate publicly facilitated studies for immune suppressed patients, who are at higher risk for glioblastoma and other cancers. Dr. Moore served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career responsible for global development within the Office of the Secretary, HHS, for Africa and other low- and middle-income regions. Dr. Moore represented HHS in cooperative international efforts in Africa to address continued health and human resources issues. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop. Dr. Moore received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Doctor of Science degree (Honoris Causa) in recognition of his distinguished public health career by Tuskegee University. Duyuru • Jun 02
NovAccess Global Inc. Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalised Healthcare Therapies NovAccess Global Inc. announced the formation of its Precision Medicine Division to enable more enhanced and accelerated personalised therapeutics and treatment protocols. Using AI, Big Data and Predictive technologies to power its new Precision Medicine Division, NovAccess Global will search through licensed databases to identify patient data (phenotypic, clinical and genomic) for analysis as part of its own and its clients therapeutic drug development and its clients' therapeutic treatment purposes. This service platform also will be marketed to external pharmaceutical and biotechnology companies, private payers, federal and national/international health agencies and healthcare providers. Beyond the glioblastoma/brain tumor segment, NovAccess Global will target cardiology and oncology patient data, with an emphasis on obtaining oncology and cardiology patient data sets from different countries around the world that will include underrepresented patient populations. The Precision Medicine Division has begun developing a platform to allow the analysis of patient data in a manner that will meet the most stringent data privacy requirements. Overall, NovAccess Global expects to have its patient data platform available for commercial use by the end of the first quarter of 2024. NovAccess Global intends to also use AI within its Precision Medicine Division to identify the most optimal antigens use for dendritic cell vaccines. Antigens are the molecules that trigger the immune response, and they need to be specific for the tumor cells and not the normal cells. AI can analyze the genomic and proteomic data of tumor cells and find the most suitable antigens for each patient. It is NovAccess Global's belief that AI can help to optimize the dose and timing of dendritic cell vaccines. The dose and timing of the vaccine can affect the efficacy and safety of the treatment. AI can use mathematical models and machine learning algorithms to predict the optimal dose and timing based on various factors such as the patient's characteristics, the tumor type and stage, and the immune status. Duyuru • Dec 30
NovAccess Global Inc. announced delayed annual 10-K filing On 12/29/2022, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Duyuru • Nov 11
Novaccess Global Inc. Appoints Peter Weinstein to Scientific Advisory Board NovAccess Global Inc. announced the appointment of Peter Weinstein, PH.D., JD to its Scientific Advisory Board. Dr. Weinstein is a well-regarded intellectual property attorney and healthcare industry consultant who has been serving as legal counsel to NovAccess Global subsidiary StemVax Therapeutics for several years. With the addition of Dr. Weinstein, the NovAccess Global Scientific Advisory Board has five members, with disciplines spanning biotechnology and medical technology IP, healthcare IT, U.S. government agency and grant submissions, oncology drug development, and clinical research. Peter D. Weinstein, Ph.D., J.D counsels in all aspects of intellectual property, transaction and corporate law. He is the founder and Chief Executive Officer of Entralta, an intellectual property management company driven to bring the high quality of work to its clients by focusing on each client's needs. In addition, he is the chief legal counsel to NovAccess Global subsidiary StemVax Therapeutics. Dr. Weinstein received his Juris Doctorate degree at Boston College Law School, and is registered patent attorney licensed to practice law in California and Texas and is admitted to U.S. District Courts located in California and Texas. He also received a Ph.D. in Biology with an emphasis in Immunology from the University of Pennsylvania. Following receipt of his Ph.D., Dr. Weinstein worked as a Research Fellow, first at the National Institutes of Health in Bethesda, Maryland and then at the United States Army Medical Research Institute of Infectious Disease in Frederick, Maryland where he investigated the molecular development of antibody diversity and worked on vaccine development. Prior to forming Entralta, Dr. Weinstein worked for many years as Senior Patent Counsel at Baxter Healthcare Corporation where he was responsible for managing legal and intellectual property matters for Baxter's major hemophilia products like Advate® and major research and development programs in hemophilia that led to the approval by the FDA of Adenovate® and VonVendi®. This work entailed working with multidisciplinary teams in the United States, Europe, and Asia. Earlier, Dr. Weinstein worked in the San Diego Offices of the law firms of Brobeck, Phleger & Harrison, and Fish & Richardson where his practice focused on the management and prosecution of patent portfolios for biotech and high tech companies and patent and general civil litigation. During law school, he worked full-time as a patent agent in the Boston Office of Goodwin Procter. Dr. Weinstein also worked as an Examiner at the United States Patent and Trademark Office followed by a stint as a Senior Scientist at a biotech company where he was responsible for the Animal Health Group developing vaccines and other therapeutics for the treatment of infectious disease in large animals. Duyuru • Nov 10
NovAccess Global Inc., Annual General Meeting, Nov 21, 2022 NovAccess Global Inc., Annual General Meeting, Nov 21, 2022, at 11:00 US Eastern Standard Time. Agenda: To consider and review the customary shareholder voting procedures and an investor presentation to be provided by the Company's management; and to discuss any other matters. Duyuru • Oct 27
NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1 NovAccess Global Inc. announced the approval of its application with the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation (ODD) for TLR-AD1, a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. Glioblastoma is a form of aggressive brain cancer that annually impacts approximately 250,000 people globally and is on the rise in many countries, according to NovAccess scientists and published reports. The market data is more alarming, with glioblastoma accounting for approximately 50% of all malignant brain cancers diagnosed in the United States each year, and more than 10,000 Americans dying from this tumor type annually. Less than 5% of people with this cancer live longer than five years after their diagnosis. The global glioblastoma treatment market was estimated to be valued in excess of $2 billion in 2020, with projections for a compounded annual growth rate of more than 8% throughout the remainder of the decade. The FDA's Office of Orphan Products Development grants orphan designation status to investigational drugs and therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States. Orphan drug designation provides benefits to drug developers which may include assistance in the drug development process, financial incentives to support clinical development, tax credits for clinical costs, exemptions from certain FDA fees and the potential for seven years of post-approval marketing exclusivity. Sponsors seeking orphan drug designation for a drug must submit a request for designation to the FDA. Orphan drug designation is a separate process from seeking commercial approval or licensing, and the receipt of orphan drug designation status does not change the regulatory requirements or process for obtaining marketing approval from the FDA. Duyuru • Aug 10
NovAccess Global Inc. announced that it expects to receive $0.1 million in funding NovAccess Global Inc. announced that it issued a convertible promissory note for gross proceeds of $100,000 to Nyla Sakakura-Clark on August 8, 2022. The note bears interest at the rate of 12% per year and is due on August 8, 2023. Duyuru • May 12
NovAccess Global Inc. announced that it has received $0.9 million in funding from AJB Capital Investments LLC On May 9, 2022, NovAccess Global Inc. closed the transaction. Duyuru • Feb 16
NovAccess Global Inc. announced delayed 10-Q filing On 02/15/2022, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Duyuru • Feb 03
NovAccess Global Inc. Announces Board Changes On January 31, 2022, NovAccess Global Inc. (‘NovAccess’) entered into a preferred stock redemption agreement (‘Agreement’) with TN3, LLC (‘TN3’), Mr. Daniel G. Martin, Irvin Consulting, LLC (‘IC’), and Dr. Dwain Morris-Irvin. Mr. Martin is the company's chairman of the board and owns TN3. Dr. Irvin is the company's chief executive officer and owns IC. Upon completion of the redemption, Mr. Martin will resign from the NovAccess board and be replaced by Dr. Irvin and John Cassarini. Duyuru • Dec 31
NovAccess Global Inc. announced delayed annual 10-K filing On 12/30/2021, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Duyuru • May 19
NovAccess Global Inc. announced delayed 10-Q filing On 05/18/2021, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Duyuru • Dec 31
NovAccess Global Inc. announced delayed annual 10-K filing On 12/30/2020, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Duyuru • Oct 29
Novaccess Global Inc. Announces Executive Changes NovAccess Global Inc. announced that L. Michael Yukich joined as fractional chief financial officer, replacing Daniel G. Martin, who had been serving as interim CFO. Mr. Martin remains chairman of the board of directors. Mike Yukich, age 74, has extensive financial and accounting experience and for the past twenty years he has held the position of chief financial officer for both public and private companies. Mr. Yukich currently serves as interim chief financial officer for Innovest Global Inc. Mr. Yukich served as Innovest’s CFO from August 2017 to October 2019 and rejoined the company in September 2020. Duyuru • Oct 16
NovAccess Global Inc. Appoints Dr. Dwain Irvin as CEO NovAccess Global Inc. announced the addition of Dr. Dwain Irvin as CEO. Dr. Irvin steps into the role after heading the Biotechnology division for Innovest Global Inc. Dr. Irvin received his PhD from UCLA School of Medicine, MPH, from UCLA School of Public Health, and trained at The Wallenberg Neuroscience Center at Lund University in Lund, Sweden. He was also a Professor, Faculty member at Cedars-Sinai Medical Center, Department of Neurosurgery. Duyuru • Aug 18
XsunX, Inc. announced delayed 10-Q filing On 08/17/2020, XsunX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 